CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Clinical Trials Arena
Original article

R1 Therapeutics secures $80.5m to fund Phase IIb AP306 study

Phase 2AP306Positive
AI Analysis

Summary

R1 Therapeutics expanded its Series A funding round to $80.5 million to advance its lead candidate AP306 in a Phase IIb trial for hyperphosphatemia in dialysis-dependent chronic kidney disease patients.

Clinical Trial Data

Phase

IIb

Importance:6/10
Sentiment:
0.70
fundingSeries APhase IIbAP306hyperphosphatemiaCKD
Related Companies

Read the original article

Published by Clinical Trials Arena on October 1, 2026 9:39 AM

Read Original